Why the study?
Factor Xa inhibitors are replacing intravenous direct thrombin inhibitors for suspected heparin-induced thrombocytopenia despite off-label indication, but whether they are cost-effective remains unclear.
Are fondaparinux and rivaroxaban cost-effective compared to argatroban in patients with suspected heparin-induced thrombocytopenia?
Population
Patients with suspected HIT based on census data from the largest Swiss hospital between 2015 and 2018
Comparison
Argatroban vs fondaparinux vs rivaroxaban
Design
Decision tree cost-effectiveness model
Authors
Loading...
Fondaparinux may reduce costs and improve outcomes versus argatroban in suspected HIT; leaves open need for randomized trials before practice change.
Are fondaparinux and rivaroxaban cost-effective compared to argatroban in patients with suspected heparin-induced thrombocytopenia?
Fondaparinux and rivaroxaban are more clinically effective and cost-effective than argatroban for suspected heparin-induced thrombocytopenia, with fondaparinux dominating argatroban.
Tuleja et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: